The FDA has rejected Sanofi's application seeking approval of tolebrutinib to treat certain forms of MS in its present form.

Disability progression in relapsing MS tends to follow one of four distinct patterns, according to a new study.

Exclusive: Scientists uncovered biological strands using artificial intelligence and hope discovery will revolutionise treatment ...

Researchers say the more they find out, the more likely 'we will be able to find treatments that can stop disease progression ...

Multiple sclerosis (MS) is a debilitating disease with few treatment options. But in a new clinical trial, scientists have tested a promising new therapy involving injections of stem cells, which ...

Multiple sclerosis (MS) is a chronic autoimmune disease characterized by the disruption of nerve signals and various ...

“Our data add and expand previous observations on silent progression in MS and are consistent with the view of the disease as a single continuum, in which RAW [relapse-associated worsening] and PIRA ...

Multiple sclerosis (MS) is a disorder that prompts the body's immune system to attack myelin, the protective sheath covering nerve cells in the brain, optic nerve and spinal cord. This can in turn ...

Disability progression independent of relapse activity (PIRA) -- sometimes referred to as silent progression -- is a key integrating concept in the contemporary view of multiple sclerosis (MS). "The ...

High levels of the periodontal bacterium Fusobacterium nucleatum may be associated with more severe disability in people with multiple sclerosis.

The progression of relapsing-onset multiple sclerosis (MS) and its associated disability may be slowing, results from a large population-based study suggest. In an evaluation of more than 7000 ...

Oral tobacco use, also known as moist snuff, is associated with slower progression of multiple sclerosis (MS), a new study shows. "Our finding that snuff use is not associated with worse disease ...